Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Update

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the target of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 49,958 shares, a decrease of 32.3% from the July 30th total of 73,790 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 50,520 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analyst Weigh In

DWTX has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating on shares of Dogwood Therapeutics in a report on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $12.00.

Hedge Funds Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 9.05% of the company’s stock.

Dogwood Therapeutics Trading Down 5.7%

Shares of NASDAQ DWTX opened at $2.48 on Thursday. The firm has a fifty day simple moving average of $1.81 and a two-hundred day simple moving average of $1.98. Dogwood Therapeutics has a 12 month low of $1.28 and a 12 month high of $9.50. The firm has a market capitalization of $84.30 million, a PE ratio of -0.28 and a beta of 1.81.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.20). On average, sell-side analysts predict that Dogwood Therapeutics will post -0.67 earnings per share for the current year.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.